Get the Stockscreener App
0.9393
19.97%
-0.2207
After Hours:
.95
0.0107
+1.14%
Invivyd Inc stock is traded at $0.9393, with a volume of 3.67M.
It is down -19.97% in the last 24 hours and down -12.42% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.16
Open:
$1.16
24h Volume:
3.67M
Relative Volume:
0.27
Market Cap:
$123.80M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.4792
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
-25.13%
1M Performance:
-12.42%
6M Performance:
+8.99%
1Y Performance:
-77.19%
1-Day Range:
$0.92
$1.16
1-Week Range:
$0.92
$1.41
52-Week Range:
$0.3546
$4.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.9393 | 123.80M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 - Yahoo Finance
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine - Yahoo Finance
Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from D. Boral Capital - Defense World
Invivyd (NASDAQ:IVVD) Given “Buy” Rating at HC Wainwright - Defense World
FDA declines Invivyd’s COVID-19 treatment EUA expansion By Investing.com - Investing.com Nigeria
IVVD Stock: More Upside For Invivyd Inc (NASDAQ: IVVD)? - Marketing Sentinel
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients - Benzinga
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday - TradingView
Invivyd says FDA declines request to expand existing EUA of PEMGARDA - TipRanks
Sector Update: Health Care - TradingView
5 Stocks That More Than Doubled Halfway Through Q1 - Zacks Investment Research
Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
FDA declines Invivyd’s COVID-19 treatment EUA expansion - Investing.com
FDA declines Invivyd's COVID-19 treatment EUA expansion By Investing.com - Investing.com South Africa
FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Chang - The Manila Times
Can PEMGARDA Still Succeed? FDA Blocks COVID Treatment Expansion but Keeps Prevention Approval - StockTitan
Invivyd news ‘disappointing’ but not in model, says H.C. Wainwright - TipRanks
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 5.2% in January - Armenian Reporter
Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far - MSN
10 Micro and Small-Cap Firms Drive Year-to-Date Gains - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Growth in Short Interest - MarketBeat
Invivyd Inc (NASDAQ: IVVD) Stock Forecast: Bearish Views Expect -505.1 Percent Drop In 2025 - Stocks Register
Holdings of Invivyd Inc (IVVD) are aligned with the stars - SETE News
How does IVVD’s price to cash per share ratio compare in the market? - US Post News
Stock Traders Purchase High Volume of Invivyd Call Options (NASDAQ:IVVD) - MarketBeat
IVVD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Invivyd Inc’s (IVVD) Stock: A Week-by-Week Analysis - The News Heater
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - The Manila Times
FY2024 Earnings Estimate for Invivyd Issued By HC Wainwright - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd Inc [IVVD] stock for 46,098 USD was sold by MCGUIRE TERRANCE - Knox Daily
Exploring High Growth Tech Stocks in the United States - Simply Wall St
Following A 407.69% Weekly Incline, Is It Still A Buy For Invivyd Inc (NASDAQ: IVVD)? - Marketing Sentinel
HC Wainwright Issues Negative Estimate for Invivyd Earnings - Defense World
Top Small Cap Stocks Worth WatchingFebruary 03rd - MarketBeat
This Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here. - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Invivyd (IVVD) Stock Rises Following Strategic Partnership - Stocks Telegraph
Invivyd tweaks COVID prophylactic playbook, teaming with NFL coach Jim Harbaugh for awareness drive - FiercePharma
Invivyd (NASDAQ:IVVD) Earns “Buy” Rating from HC Wainwright - Defense World
Los Angeles Chargers coach Jim Harbaugh reminds people COVID isn’t a cold - MM+M Online
Brokers Offer Predictions for Invivyd FY2029 Earnings - Defense World
Invivyd Inc Reports Q4 2024 Revenue of $13.8 Million, Slightly B - GuruFocus.com
H.C. Wainwright maintains Buy rating on Invivyd stock at $10 target - MSN
(IVVD)Analyzing Invivyd's Short Interest - Benzinga
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold - The Manila Times
Football Legend Jim Harbaugh Joins Forces with Invivyd as COVID Deaths Surge: One American Lost Every 9 Minutes - StockTitan
Analysts’ Revisions Show Improving Sentiment For Invivyd Inc (NASDAQ: IVVD) - Stocks Register
D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD) - Defense World
I See The Bull Case For Invivyd, But I’m Not Married To It (NASDAQ:IVVD) - Seeking Alpha
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
| MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
| MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
| MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
| MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
| MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
6.60%
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):